A Study of Effectiveness and Safety of the First-Line Nivolumab Plus Ipilimumab With or Without Chemotherapy for Advanced/Recurrent Non-Small Cell Lung Cancer in Japan
Clinical trial NCT05161325 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05161325
- Sponsor
- Bristol-Myers Squibb
- Status
- ACTIVE_NOT_RECRUITING
- Study type
- OBSERVATIONAL
- Start date
- 2020-12-15
- Primary completion
- 2026-12-31
- Enrollment
- 525
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.